Flagging message

As of March 24, Fårö Capital AB has sold 300,000 shares in EQL Pharma, corresponding to approximately 1 percent of the votes and capital in EQL Pharma.

The transaction has taken place in a block entry outside the market at a price of SEK 37.5 per share in EQL Pharma. Before the transaction, Fårö Capital owned 8,727,348 shares, corresponding to approximately 30% of the votes and capital in EQL Pharma. After the transaction, Fårö Capital owns approximately 29 percent of the votes and capital in EQL Pharma.

The sale was prompted by the fact that a number of the major Swedish investment banks considered that the proportion of institutional ownership and the liquidity in the share needed to increase.

For further information, please contact:
Axel Schörling
CEO & President, EQL Pharma AB (publ)

Phone: +46 (0) 763 – 17 90 60
E-mail: axel.schorling@eqlpharma.com
Website: www.eqlpharma.com

EQL Pharma AB (publ) in short

EQL Pharma AB specializes in developing and selling niche pharmaceuticals. The company currently has more than 20 niche generics (ie generics with limited competition apart from the reference pharmaceutical) approved in the Nordic markets and a couple of originals. In addition to these, there is a significant pipeline of mainly niche generics for launch in 2023 and beyond. The business is currently entirely focused on prescription pharmaceuticals, including hospital products, in the Nordic region and in selected European markets. EQL Pharma AB conducts its operations in Lund and is listed on the Spotlight Stock Market. EQL Pharma AB conducts extensive development work in collaboration with leading contract manufacturers and pharmaceutical companies in the EU and Asia, among others.